144 related articles for article (PubMed ID: 38426337)
1. The role of progestin subdermal implant in the management of adenomyosis: a systematic review.
Chene G; Baffet H; Cerruto E; Nohuz E; Agostini A
Eur J Contracept Reprod Health Care; 2024 Apr; 29(2):61-68. PubMed ID: 38426337
[TBL] [Abstract][Full Text] [Related]
2. The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review.
Ambacher K; Secter M; Sanders AP
Curr Med Res Opin; 2022 Mar; 38(3):479-486. PubMed ID: 35048754
[TBL] [Abstract][Full Text] [Related]
3. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mg levonorgestrel-releasing intrauterine system for up to 24 months.
Margatho D; Carvalho NM; Bahamondes L
Eur J Contracept Reprod Health Care; 2020 Apr; 25(2):133-140. PubMed ID: 32069126
[No Abstract] [Full Text] [Related]
4. Safety and Benefits of Contraceptives Implants: A Systematic Review.
Rocca ML; Palumbo AR; Visconti F; Di Carlo C
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34201123
[TBL] [Abstract][Full Text] [Related]
5. Effects of Etonogestrel implants on pelvic pain and menstrual flow in women suffering from adenomyosis or endometriosis: Results from a prospective, observational study.
Niu X; Luo Q; Wang C; Zhu L; Huang L
Medicine (Baltimore); 2021 Feb; 100(6):e24597. PubMed ID: 33578561
[TBL] [Abstract][Full Text] [Related]
6. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
[TBL] [Abstract][Full Text] [Related]
7. Long-acting reversible contraception with etonogestrel implants in female macaques (
Maaskant A; Scarsi KK; Meijer L; Roubos S; Louwerse AL; Remarque EJ; Langermans JAM; Stammes MA; Bakker J
Front Vet Sci; 2023; 10():1319862. PubMed ID: 38260208
[TBL] [Abstract][Full Text] [Related]
8. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
[TBL] [Abstract][Full Text] [Related]
9. Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.
Margatho D; Mota Carvalho N; Eloy L; Bahamondes L
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):344-350. PubMed ID: 30372645
[TBL] [Abstract][Full Text] [Related]
10. Subdermal contraceptive implants.
Peralta O; Diaz S; Croxatto H
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
[TBL] [Abstract][Full Text] [Related]
11. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial.
Choudhury S; Jena SK; Mitra S; Padhy BM; Mohakud S
Ther Adv Reprod Health; 2024; 18():26334941241227401. PubMed ID: 38283750
[TBL] [Abstract][Full Text] [Related]
14. A clinical observational study on the efficacy of subcutaneous etonogestrel implants for adenomyosis in 20 patients.
Nie L; Zou H; Ma X; Cheng L; Jiao J; Wang F; Liang W; Zhang P
Gynecol Endocrinol; 2021 Aug; 37(8):735-739. PubMed ID: 34160336
[No Abstract] [Full Text] [Related]
15. Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive.
Hohmann H
Patient Prefer Adherence; 2009 Nov; 3():205-11. PubMed ID: 19936163
[TBL] [Abstract][Full Text] [Related]
16. Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report.
Ferreira-Filho ES; Bahamondes L; Duarte DC; Guimarães ALM; de Almeida PG; Soares-Júnior JM; Baracat EC; Sorpreso ICE
Gynecol Endocrinol; 2022 Jan; 38(1):90-93. PubMed ID: 34486922
[TBL] [Abstract][Full Text] [Related]
17. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
Laurikka-Routti M; Haukkamaa M
Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports.
Nie LK; Zou HL; Cheng L; Zhang PH
J Obstet Gynaecol Res; 2022 Jan; 48(1):262-265. PubMed ID: 34713941
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).
Yisa SB; Okenwa AA; Husemeyer RP
J Fam Plann Reprod Health Care; 2005 Jan; 31(1):67-70. PubMed ID: 15720856
[TBL] [Abstract][Full Text] [Related]
20. Long-Acting Reversible Etonogestrel Subdermal Implant in Adolescents.
Hoffman ND; Alderman EM
Pediatr Rev; 2024 Jan; 45(1):3-13. PubMed ID: 38161157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
